Literature DB >> 10644339

Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine.

H Gahéry-Ségard1, G Pialoux, B Charmeteau, S Sermet, H Poncelet, M Raux, A Tartar, J P Lévy, H Gras-Masse, J G Guillet.   

Abstract

We have attempted to develop an anti-human immunodeficiency virus (HIV) lipopeptide vaccine with several HIV-specific long peptides modified by C-terminal addition of a single palmitoyl chain. A mixture of six lipopeptides derived from regulatory or structural HIV-1 proteins (Nef, Gag, and Env) was prepared. A phase I study was conducted to evaluate immunogenicity and tolerance in lipopeptide vaccination of HIV-1-seronegative volunteers given three injections of either 100, 250, or 500 microg of each lipopeptide, with or without immunoadjuvant (QS21). This report analyzes in detail B- and T-cell responses induced by vaccination. The lipopeptide vaccine elicited strong and multiepitopic B- and T-cell responses. Vaccinated subjects produced specific immunoglobulin G antibodies that recognized the Nef and Gag proteins. After the third injection, helper CD4(+)-T-cell responses as well as specific cytotoxic CD8(+) T cells were also obtained. These CD8(+) T cells were able to recognize naturally processed viral proteins. Finally, specific gamma interferon-secreting CD8(+) T cells were also detected ex vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644339      PMCID: PMC111644          DOI: 10.1128/jvi.74.4.1694-1703.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Do beta-chemokines have clinical relevance in HIV infection?

Authors:  C E Mackewicz; E Barker; G Greco; G Reyes-Teran; J A Levy
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

2.  Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides.

Authors:  J P Sauzet; H Gras-Masse; J G Guillet; E Gomard
Journal:  Int Immunol       Date:  1996-04       Impact factor: 4.823

3.  Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers.

Authors:  G Ferrari; W Humphrey; M J McElrath; J L Excler; A M Duliege; M L Clements; L C Corey; D P Bolognesi; K J Weinhold
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees.

Authors:  L BenMohamed; H Gras-Masse; A Tartar; P Daubersies; K Brahimi; M Bossus; A Thomas; P Druilhe
Journal:  Eur J Immunol       Date:  1997-05       Impact factor: 5.532

5.  Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression.

Authors:  S Koenig; A J Conley; Y A Brewah; G M Jones; S Leath; L J Boots; V Davey; G Pantaleo; J F Demarest; C Carter
Journal:  Nat Med       Date:  1995-04       Impact factor: 53.440

6.  Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides.

Authors:  J P Sauzet; B Déprez; F Martinon; J G Guillet; H Gras-Masse; E Gomard
Journal:  Vaccine       Date:  1995-10       Impact factor: 3.641

7.  The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection.

Authors:  B D Livingston; C Crimi; H Grey; G Ishioka; F V Chisari; J Fikes; H Grey; R W Chesnut; A Sette
Journal:  J Immunol       Date:  1997-08-01       Impact factor: 5.422

8.  Extracellular Nef protein regulates productive HIV-1 infection from latency.

Authors:  K Fujinaga; Q Zhong; T Nakaya; M Kameoka; T Meguro; K Yamada; K Ikuta
Journal:  J Immunol       Date:  1995-12-01       Impact factor: 5.422

9.  Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.

Authors:  A Vitiello; G Ishioka; H M Grey; R Rose; P Farness; R LaFond; L Yuan; F V Chisari; J Furze; R Bartholomeuz
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

10.  The carboxyl-terminal region of HIV-1 Nef protein is a cell surface domain that can interact with CD4+ T cells.

Authors:  K Otake; Y Fujii; T Nakaya; Y Nishino; Q Zhong; K Fujinaga; M Kameoka; K Ohki; K Ikuta
Journal:  J Immunol       Date:  1994-12-15       Impact factor: 5.422

View more
  29 in total

1.  Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells.

Authors:  Kuan-Yin Shen; Ying-Chyi Song; I-Hua Chen; Chih-Hsiang Leng; Hsin-Wei Chen; Hui-Ju Li; Pele Chong; Shih-Jen Liu
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

2.  Lipidation of T helper sequences from hepatitis C virus core significantly enhances T-cell activity in vitro.

Authors:  B Langhans; I Braunschweiger; S Schweitzer; G Jung; G Inchauspé; T Sauerbruch; U Spengler
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

3.  Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV.

Authors:  Anne S De Groot; Daniel S Rivera; Julie A McMurry; Soren Buus; William Martin
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

4.  Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1.

Authors:  W M Cohen; A Bianco; F Connan; L Camoin; M Dalod; G Lauvau; E Ferriès; B Culmann-Penciolelli; P M van Endert; J P Briand; J Choppin; J G Guillet
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

5.  Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

Authors:  Hanne Gahéry-Ségard; Gilles Pialoux; Suzanne Figueiredo; Céline Igéa; Mathieu Surenaud; Jessintha Gaston; Helene Gras-Masse; Jean-Paul Lévy; Jean-Gérard Guillet
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  HIV Vaccines: Biological and Clinical Considerations.

Authors:  M. Patricia D'Souza; Mary A. Allen; Margaret I. Johnston
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

7.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.

Authors:  Paul Spearman; Spyros Kalams; Marnie Elizaga; Barbara Metch; Ya-Lin Chiu; Mary Allen; Kent J Weinhold; Guido Ferrari; Scott D Parker; M Juliana McElrath; Sharon E Frey; Jonathan D Fuchs; Michael C Keefer; Michael D Lubeck; Michael Egan; Ralph Braun; John H Eldridge; Barton F Haynes; Lawrence Corey
Journal:  Vaccine       Date:  2008-11-07       Impact factor: 3.641

8.  TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Qi Wang; Guangming Li; Riddhima Banga; Jianping Ma; Haisheng Yu; Fumihiko Yasui; Zheng Zhang; Giuseppe Pantaleo; Matthieu Perreau; Sandra Zurawski; Gerard Zurawski; Yves Levy; Lishan Su
Journal:  J Clin Invest       Date:  2018-08-27       Impact factor: 14.808

9.  Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells.

Authors:  Anne-Laure Flamar; Yaming Xue; Sandra M Zurawski; Monica Montes; Bryan King; Louis Sloan; SangKon Oh; Jacques Banchereau; Yves Levy; Gerard Zurawski
Journal:  AIDS       Date:  2013-08-24       Impact factor: 4.177

10.  Immune response to Lactobacillus plantarum expressing Borrelia burgdorferi OspA is modulated by the lipid modification of the antigen.

Authors:  Beatriz del Rio; Jos F M L Seegers; Maria Gomes-Solecki
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.